Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 first-in-human study of DCC-3116 alone and with sotorasib in RAS/MAPK-mutant advanced solid tumors
2022-501474-19-00Phase 2Completed
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of inlexisertib and sotorasib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (2 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoint: Objective response rate. Started Jan 2024; status: completed.
02
Drugs
inlexisertibsotorasib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-501474-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501474-19-00.